News Conference News EuroPCR 2018 Chinese Firehawk Stent Performs Well Against Xience in All-Comers Study Michael O'Riordan May 29, 2018
News Conference News EuroPCR 2018 New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes Michael O'Riordan May 25, 2018
News Conference News EuroPCR 2018 Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents Shelley Wood May 24, 2018
News Conference News EuroPCR 2018 EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage Shelley Wood May 17, 2018
News Conference News SCAI 2018 Interventional Appetite Erodes for Dissolving Polymers and Scaffolds Shelley Wood May 04, 2018
News Conference News ACC 2018 Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues Michael O'Riordan March 11, 2018
News Conference News TCT 2017 Long-term Absorb BVS Data Continue to Disappoint Michael O'Riordan October 31, 2017
News Conference News TCT 2017 DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis Todd Neale October 30, 2017
News Conference News ESC 2017 BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months Shelley Wood August 30, 2017
News Conference News EuroPCR 2017 Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis Michael O'Riordan May 19, 2017
News Conference News EuroPCR 2017 No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan Michael O'Riordan May 17, 2017
News Conference News EuroPCR 2017 DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit Michael O'Riordan May 16, 2017
News Conference News EuroPCR 2017 Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate Michael O'Riordan May 15, 2017
News Conference News SCAI 2017 Bioresorbable Scaffolds: Where Do We Go From Here? L.A. McKeown May 15, 2017
News Conference News EuroPCR 2017 EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40 Shelley Wood May 12, 2017
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017